Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Buys 59,880 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 59,880 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The stock was acquired at an average cost of $9.96 per share, with a total value of $596,404.80. Following the completion of the acquisition, the director directly owned 17,242,483 shares of the company’s stock, valued at $171,735,130.68. The trade was a 0.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. purchased 41,319 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.93 per share, for a total transaction of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, with a total value of $3,351,032.83.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $10.53 on Wednesday. The company has a 50 day moving average price of $8.87 and a 200 day moving average price of $7.42. Artiva Biotherapeutics, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $14.53. The stock has a market capitalization of $260.30 million, a PE ratio of -2.97 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Wedbush upped their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ARTV. Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics in the second quarter valued at about $53,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics in the second quarter valued at about $58,000. Finally, Jane Street Group LLC bought a new position in Artiva Biotherapeutics during the second quarter worth about $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.